NBE Therapeutics
Mariarosa Spina Horn has worked for three companies over the past 26 years. From 1994 to 2000, they worked as a Research Associate at The Scripps Research Institute. From 2000 to 2014, they were a Research Scientist and Project Leader at Otto-von-Guericke-University Magdeburg, where they were funded by the German Research Foundation and Spitzenbonus Project NBL3. Finally, from 2014 to present, they have been a Human Resources Manager and Management Assistant, a Management Assistant and Head of Human Resources, and a Management Assistant and HR Responsible at NBE-Therapeutics AG.
Mariarosa Spina Horn received their Master's degree in Biology from Alma Mater Studiorum – Università di Bologna between 1986 and 1993. Following this, they were a Post-Graduate Trainee at the Institute of Human Physiology of the same university from 1993 to 1994. In 1998, they completed their Ph.D. in Neurobiology and Neurosciences at Otto-von-Guericke University Magdeburg. Most recently, in 2020, they attended NSH Bildungszentrum for Personnel Administration/Human Resources Management.
This person is not in any teams
This person is not in any offices
NBE Therapeutics
1 followers
NBE-Therapeutics is developing best-in-class cancer therapies to increase survival and improve quality of life for cancer patients worldwide. The company’s next-generation immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate (ADC) platform. This best-in-class ADC platform creates highly potent and safe immune-stimulatory ADCs ("iADCs™") with an anthracycline payload, not only directly targeting tumor cells, but also inducing a long-lasting immunological anti-tumor effect. The company’s lead asset, NBE-002, an anti-ROR1 ADC, is due to start first-in-human clinical trials in three US centers by the end of 2020, focusing on triple negative breast cancer, but also other solid cancer indications which express ROR1. NBE-Therapeutics is a privately owned biotech company based in Basel, financed by Germany’s Boehringer Ingelheim Venture Fund, the Czech Republic’s PPF Group and Denmark’s Novo Holdings as international institutional investors, and by Swiss, German, and Dutch private investors. The company has raised over USD 65m, including a USD 22m Series C (2020), two USD 20m Series B rounds (2016 & 2018), a USD 3m Series A (2015), and over USD 4m from several non-dilutive grants from organizations including the Swiss Commission for Technology & Innovation, the European Commission, and Systems-X.